GlassScriptPhysician profile
Maureen Gottfried
NPI 1972652832
$961.84
in general payments reported to CMS, 2019-2025
29 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.93 · 2020: $29.76 · 2021: $112 · 2022: $339 · 2023: $270 · 2024: $94.65 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $465.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $171.94 | 2021-2025 | |
| Harmony Biosciences LLC | $95.11 | 2022-2023 | Wakix |
| Alexion Pharmaceuticals, INC. | $58.97 | 2021-2023 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $46.59 | 2022-2024 | Austedo Xr |
| Sk Life Science, INC. | $42.40 | 2022-2023 | |
| Impel Pharmaceuticals INC. | $35.96 | 2022-2023 | Trudhesa |
| Ucb, INC. | $34.37 | 2023 | Briviact |
| Janssen Biotech, INC. | $32.93 | 2023-2024 | Tremfya |
| Argenx US, INC. | $32.39 | 2022-2023 | Vyvgart |
| Boston Scientific Corporation | $31.33 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $30.65 | 2021 | |
| Lundbeck LLC | $30.65 | 2022-2023 | Vyepti |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2020 | |
| Genentech USA, INC. | $27.83 | 2024 | Ocrevus, Enspryng |
| Jazz Pharmaceuticals INC. | $27.40 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $25.79 | 2022-2023 | Amyvid |
| Emd Serono, INC. | $24.74 | 2022 | |
| Eisai INC. | $20.05 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $19.32 | 2025 | Rexulti |
| Upsher-Smith Laboratories LLC | $15.58 | 2021 | |
| Ani Pharmaceuticals, INC. | $15.45 | 2024 | Purified Cortrophin Gel |
| Tg Therapeutics, INC. | $15.06 | 2025 | |
| Amgen INC. | $14.95 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.93 | 2019 | |
| Neurelis, INC. | $14.74 | 2023 | Valtoco |
| Genzyme Corporation | $14.25 | 2022 | |
| Aprecia Pharmaceuticals, LLC | $14.06 | 2022 | |
| W. L. Gore & Associates, INC. | $12.84 | 2021 | |
| Biogen, INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Gottfried listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.